After Demand Climbed With COVID-19, Abbott Expects Continued Nutritional Line Sales Growth
Post-Pandemic OTC Diagnostics Sales Also Look Promising To Firm
Executive Summary
CEO Robert Ford says “dynamics” of more consumers fortifying their diets to promote immunity from COVID-19 “are driving strong growth for our Ensure and Glucerna brands.” Analysts don't share Ford's confidence, though, for continued OTC diagnostics sales growth.
You may also be interested in...
HBW Executive Decisions: Clasado Sales Heads, CRN Scholars, PanTheryx Early Nutrition SVP
Clasado appoints APAC, EMEA and North America sales directors; CRN, American Society for Nutrition award students; DSM Veteran joins PanTheryx as early life nutrition SVP; Ford chairs Abbott board as White leaves; and turnover at Turning Point helm.
OTC COVID-19 Tests Have Abbott Seeing Continuing Demand For At-Home Diagnostics
“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.